Journal
EUROPEAN JOURNAL OF HEART FAILURE
Volume 12, Issue 6, Pages 549-556Publisher
WILEY
DOI: 10.1093/eurjhf/hfq055
Keywords
Heart failure; Prognosis; Biomarkers; GISSI-HF; Chromogranin A
Categories
Funding
- GISSI-HF
- Italian Health Ministry [RF-FCG-2006-379933, PS-RIABILex56/05/10]
- South-Eastern Norway Regional Health Authority
- Norwegian Heart and Lung Foundation
- Akershus University Hospital
Ask authors/readers for more resources
To assess the association between circulating levels of chromogranin A (CgA) and outcome in a large population of patients with chronic heart failure (HF). Plasma CgA levels were measured at randomization and after 3 months in 1233 patients (median age 68 years, 80% male) with chronic, stable HF from the GISSI-HF trial. Circulating CgA levels were associated with several established risk markers in HF, including increased age, diabetes, reduced renal function, and heart rate variability. During a median follow-up of 3.9 years, 333 patients (27%) died. By univariable analysis, plasma CgA levels at baseline were strongly associated with all-cause mortality during follow-up; 2nd vs. 1st tertile: HR 1.58 (1.17-2.11), P = 0.002; and 3rd vs. 1st tertile: HR 2.35 (1.78-3.10), P < 0.0001. After adjustment for established risk factors of mortality, this association was attenuated and no longer significant. Randomized treatments with n-3 polyunsaturated fatty acid or rosuvastatin did not significantly change plasma CgA concentration over 3 months. Measurement of circulating CgA levels in patients with chronic, stable HF does not provide incremental prognostic information to that obtained from physical examination, routine biochemical analysis, and contemporary HF biomarkers.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available